Determining the Safety and Effectiveness of Olanzapine in Children and Adolescents
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00183612 |
|
Recruitment Status :
Terminated
First Posted : September 16, 2005
Last Update Posted : January 8, 2014
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Bipolar Disorder Psychotic Disorders | Drug: Olanzapine | Not Applicable |
Numerous advancements in mental health treatment have been made over the past decade. Unfortunately, these advancements have focused on adults and have not been fully extended to children and adolescents. With limited pediatric information on the pharmacokinetics and pharmacodynamics for drugs used to treat mental health problems, psychiatrists are prescribing drugs for children using data extrapolated from adults, which may lead to potentially life-threatening results. Olanzapine is widely prescribed to treat both children and adults. This study will determine the safety and effectiveness of olanzapine in children and adolescents with mental health disorders. The study will also compare the effects of gender, development, body composition, and metabolic genotype and phenotype on how olanzapine works.
All participants will receive olanzapine for up to 8 weeks. Blood collection will occur at each weekly study visit. On Visit 1, participants will receive their first dose of olanzapine and repeated blood collection will occur every hour for 24 hours. Blood collection will be used to determine the time it takes for olanzapine to be absorbed into the body, its duration of action, the extent of its distribution in the body, the manner in which it is excreted from the body, and its effects on organs of the body.
| Study Type : | Interventional (Clinical Trial) |
| Enrollment : | 68 participants |
| Allocation: | Non-Randomized |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Developmental Pharmacokinetics of Psychotropic Drugs: Olanzapine |
| Study Start Date : | May 2000 |
| Actual Primary Completion Date : | April 2007 |
| Actual Study Completion Date : | April 2007 |
- Olanzapine pharmacokinetics, safety, and effectiveness [ Time Frame: Measured over 8 weeks ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 6 Years to 18 Years (Child, Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Diagnosis of bipolar disorder with mania, mixed mania, or psychosis not otherwise specified
- Meet certain laboratory result requirements
- Have taken either lithium or valproate for 4 weeks or longer with no or only partial response
- Parent or guardian willing to provide informed consent
Exclusion Criteria:
- History of other serious unstable illness requiring medication
- Diabetes mellitus
- Abnormal physical examination and electrocardiogram (EKG) results
- At risk for suicide or homicide (based on an assessment of suicidal history, intent or plan, mental state, mood, and substance use)
- IQ less than 65
- History of organic brain disease or seizure disorder
- Recent exposure to an infectious disease, such as tuberculosis (TB) or meningitis
- Current use of drugs that may interfere with the metabolism of olanzapine and unwilling to discontinue use during the study
- Body mass index (BMI) less than the 5th OR greater than the 95th percentile for age and gender
- History of smoking within 1 year prior to study entry
- Pregnancy or breastfeeding
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00183612
| United States, Massachusetts | |
| McLean Hospital | |
| Belmont, Massachusetts, United States, 02478 | |
| Cambridge Health Alliance | |
| Medford, Massachusetts, United States, 02155 | |
| Principal Investigator: | Louise G. Cohen, PharmD | Massachusetts General Hospital |
| Responsible Party: | Maurizio Fava, MD, MD, Massachusetts General Hospital |
| ClinicalTrials.gov Identifier: | NCT00183612 History of Changes |
| Other Study ID Numbers: |
K08MH001765 ( U.S. NIH Grant/Contract ) K08MH001765 ( U.S. NIH Grant/Contract ) DSIR CT-M |
| First Posted: | September 16, 2005 Key Record Dates |
| Last Update Posted: | January 8, 2014 |
| Last Verified: | January 2014 |
Keywords provided by Maurizio Fava, MD, Massachusetts General Hospital:
|
Child Adolescent Mental Health |
Olanzapine Pharmacokinetics Pharmacology |
Additional relevant MeSH terms:
|
Disease Bipolar Disorder Psychotic Disorders Mental Disorders Pathologic Processes Bipolar and Related Disorders Schizophrenia Spectrum and Other Psychotic Disorders Olanzapine Antiemetics Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs |
Gastrointestinal Agents Antipsychotic Agents Tranquilizing Agents Central Nervous System Depressants Psychotropic Drugs Serotonin Uptake Inhibitors Neurotransmitter Uptake Inhibitors Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action Neurotransmitter Agents Serotonin Agents |